Autopsy report · NCT00987545
Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence
Cause of deathOther
“Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part I of the study.”
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 1 year 5 months before it stopped.
- 3 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Keloids
- Interventions
- QAX576; QAX576 placebo
- Participants
- 3
- Sites
- 4
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.